Press Releases March 31, 2026 05:40 PM

Cloudastructure Inc. Reschedules Fourth Quarter 2025 Financial Results and Business Update Conference Call

Cloudastructure reschedules Q4 2025 financial results and business update conference call to April 1, 2026.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CSAI

Cloudastructure, Inc., a leader in AI surveillance and remote guarding, announced the rescheduling of its conference call to discuss fourth quarter 2025 financial results and business update to April 1, 2026. The call will be accessible via telephone and webcast, with replays available afterward. The company specializes in cloud-based video surveillance with AI/ML analytics, offering contract-free, month-to-month pricing and 24/7 support, aiming to deliver enhanced security solutions and reduced total ownership costs.

Cloudastructure Inc. Reschedules Fourth Quarter 2025 Financial Results and Business Update Conference Call
CSAI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Conference call for Q4 2025 financial results and business update rescheduled to April 1, 2026.
  • Cloudastructure provides AI-powered cloud video surveillance with a scalable, contract-free platform targeting enterprise security needs.
  • The company emphasizes cost efficiency, promising up to 75% lower total cost of ownership versus competitors.

PALO ALTO, CA, March 31, 2026 (GLOBE NEWSWIRE) -- Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”) an award-winning leader in AI Surveillance and Remote Guarding, today announced that its previously scheduled conference call to discuss fourth quarter 2025 financial results and provide a business update has been rescheduled to Wednesday, April 1, 2026, at 12:00 PM Eastern Time.

The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 708707. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/3134/53730 or on the investor relations section of the company’s website, https://investor.cloudastructure.com/.

A webcast replay will be available on the investor relations section of the Company’s website at https://investor.cloudastructure.com/ through March 31, 2027. A telephone replay of the call will be available approximately one hour following the call, through April 14, 2026, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 53730.

ABOUT CLOUDASTRUCTURE

Headquartered in Palo Alto, California, Cloudastructure’s advanced award-winning security platform utilizes a scalable cloud-based architecture that features cloud video surveillance with proprietary, state-of-the-art AI/ML analytics, and a seamless remote guarding solution. The combination enables enterprise businesses to achieve proactive, end-to-end security, and pairs that platform with an attractive value proposition that eschews proprietary hardware and offers contract-free, month-to-month pricing and unlimited 24/7 support. With Cloudastructure, companies can achieve unparalleled situational awareness in real time and thereby stop crime as it is happening, while simultaneously achieving up to a 75% lower Total Cost of Ownership than other systems. For more information, visit https://www.cloudastructure.com/.

Forward-Looking Statements

Media Contact:
Kathleen Hannon
Sr. Communications Director
Cloudastructure, Inc.
[email protected]
(704) 574-3732

Investor Contact:
Crescendo Communications, LLC
212-671-1020
[email protected]


Risks

  • The announcement involves only scheduling changes with no new financial or operational data, which may limit immediate market impact.
  • Dependence on the adoption of advanced AI/ML surveillance technology may face competitive and technological challenges.
  • Potential uncertainties in the timing and impact of financial results and updates could affect investor sentiment.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026